All In MedTech

Device Trial Radar · NCT06111365

Pivotal Observational CHLOE Study

A Pivotal, Observational, Prospective Assessment Study to Assess the Performance of Fairtility CHLOE BLAST™ Algorithm for the Prediction of Blastocyst Formation in Women Undergoing In-vitro Fertilization

Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

59

Actual

Start

Jan 22, 2024

Primary completion

Aug 12, 2024

Study completion Aug 12, 2024

Sponsor

Lead sponsor
FairtilityNot on our public-company list
Sponsor type
Industry
First posted
Nov 1, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pivotal study is an observational, prospective assessment, multi-center, databank based, clinical study aimed to evaluate the performance of CHLOE™ algorithm in prediction of blastocyst formation.

Conditions

  • IVF

Interventions

  • CHLOEDevice

    the system will provide to the user a "CHLOE™ score", which is a blastocyst development prediction value, a discrete grading for blastocyst associated with the likelihood of the embryo reaching the blastocyst stage at Day 5

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Odds Ratio (OR) for the adjunct prediction of blastulation is required to be statistically significantly greater than 1Time frame: day 5

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Weill Cornell Medicine

    New York, New York

  • Cleveland Clinic Fertility

    Cleveland, Ohio

  • Dallas Fertility Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.